Carregant...

Roles of EGFR and KRAS Mutations in the Treatment Of Patients With Non–Small-Cell Lung Cancer

After decades of empirical treatment, molecular subtypes of non–small-cell lung cancer (NSCLC) are now emerging that may enable us to target treatment for patients and increase the likelihood of response. Of the biomarkers under evaluation, gene mutations are gaining recognition as predictive marker...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autor principal: Langer, Corey J.
Format: Artigo
Idioma:Inglês
Publicat: MediMedia USA, Inc. 2011
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3138369/
https://ncbi.nlm.nih.gov/pubmed/21785539
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!